drugset / Trial / NCT06837922
Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
RandomizedParallel-groupDouble-blindTreatment
Summary
A randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in adolescent and adult patients with moderate to severe asthma.
Timeline
- Start
- 2025-03-25
- Primary completion
- 2027-11-15
- Completion
- 2028-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COMEKIBART | Monoclonal antibody | — | Subcutaneous |